ECSP22066666A - Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético - Google Patents

Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético

Info

Publication number
ECSP22066666A
ECSP22066666A ECSENADI202266666A ECDI202266666A ECSP22066666A EC SP22066666 A ECSP22066666 A EC SP22066666A EC SENADI202266666 A ECSENADI202266666 A EC SENADI202266666A EC DI202266666 A ECDI202266666 A EC DI202266666A EC SP22066666 A ECSP22066666 A EC SP22066666A
Authority
EC
Ecuador
Prior art keywords
piperazin
methoxyphenyl
trifluoromethyl
fluoro
methoxy
Prior art date
Application number
ECSENADI202266666A
Other languages
English (en)
Inventor
Thomas Goldner
Bertran Jordi Carles Ceron
Helmut Buschmann
Original Assignee
Aic246 Ag Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag Co Kg filed Critical Aic246 Ag Co Kg
Publication of ECSP22066666A publication Critical patent/ECSP22066666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la sal de potasio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4Hquinazolin-4-il] acético y solvatos de la misma. La invención se refiere además a métodos de preparación de dicha sal de potasio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético o solvatos de la misma, así como composiciones farmacéuticas que comprenden dicha sal.
ECSENADI202266666A 2020-02-27 2022-08-24 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético ECSP22066666A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159742 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22066666A true ECSP22066666A (es) 2022-12-30

Family

ID=69742731

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202266666A ECSP22066666A (es) 2020-02-27 2022-08-24 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético

Country Status (21)

Country Link
US (1) US20230150950A1 (es)
EP (1) EP4110471A1 (es)
JP (1) JP7512405B2 (es)
KR (1) KR20220148860A (es)
CN (1) CN115427112B (es)
AR (1) AR121437A1 (es)
AU (1) AU2021227281B2 (es)
BR (1) BR112022016890A2 (es)
CA (1) CA3169075A1 (es)
CL (1) CL2022002294A1 (es)
CO (1) CO2022012006A2 (es)
CU (1) CU20220046A7 (es)
EC (1) ECSP22066666A (es)
IL (1) IL295644A (es)
MX (1) MX2022010442A (es)
MY (1) MY210500A (es)
PE (1) PE20230512A1 (es)
PY (1) PY2116973A (es)
TW (1) TWI819279B (es)
UY (1) UY39097A (es)
WO (1) WO2021170882A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY40078A (es) * 2021-12-21 2023-06-30 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin
PY24113872A (es) 2023-12-21 2025-07-29 Aic 246 Ag & Co Kg Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.-

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
US20230150950A1 (en) 2023-05-18
CN115427112A (zh) 2022-12-02
UY39097A (es) 2021-09-30
CU20220046A7 (es) 2023-04-10
AU2021227281A1 (en) 2022-10-13
EP4110471A1 (en) 2023-01-04
KR20220148860A (ko) 2022-11-07
CN115427112B (zh) 2024-10-11
AU2021227281B2 (en) 2024-07-18
MY210500A (en) 2025-09-26
CL2022002294A1 (es) 2023-02-03
TWI819279B (zh) 2023-10-21
MX2022010442A (es) 2022-10-18
CA3169075A1 (en) 2021-09-02
NZ792572A (en) 2025-07-25
BR112022016890A2 (pt) 2022-12-06
WO2021170882A1 (en) 2021-09-02
PE20230512A1 (es) 2023-03-24
PY2116973A (es) 2021-11-18
IL295644A (en) 2022-10-01
TW202140455A (zh) 2021-11-01
JP7512405B2 (ja) 2024-07-08
AR121437A1 (es) 2022-06-08
CO2022012006A2 (es) 2022-11-18
JP2023524349A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
MX2020013726A (es) Compuestos antagonistas de pcsk9.
CY1117796T1 (el) Μετα νατριου και ασβεστιου αλατα παραγωγου διυδροκινζολινης και η χρηση αυτων ως αντι-ιικα μεσα
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
ECSP22066666A (es) Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético
BR112015021027A2 (pt) compostos terapêuticos
PE20160863A1 (es) Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CO6280440A2 (es) Derivados de aminobenzamida como agentes utiles para el control de parasito de animales
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
CY1118284T1 (el) Βεσυλικα και τοσυλικα αλατα ενος παραγωγου διυδροκιναζολινης και χρηση αυτων ως αντιικων παραγοντων
EA201891120A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
NZ628444A (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
MX2019012505A (es) Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
CL2024000755A1 (es) Sal de calcio de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
EA201491288A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ БРЕКСПИПРАЗОЛ И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН
MX385295B (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
ECSP22066670A (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
GEP20257828B (en) Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl) piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
BR112022016931A2 (pt) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sódio e composições farmacêuticas do mesmo
BR112015011849A2 (pt) método de preparação de formas de cristal de 4 (ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metoxipiridina-2-carboxamida e formas de cristal da mesma